

## A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

**Status:** Recruiting

### Eligibility Criteria

This study is NOT accepting healthy volunteers

### Conditions & Interventions

**Conditions:**

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

### More Information

**Contact(s):** Lauren Aase - lauren.aase@parknicollet.com

**Principal Investigator:** Birendra Kumar

**Phase:** Phase III

**IRB Number:** 0123456789

**System ID:** NCT03701282

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.